Rubella virus

Fields Virology: Sixth Edition

Volumn 1, Issue , 2013, Pages

  Hobman, Tom C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904992025     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (265)

1. Abernathy ES, Wang CY, Frey TK. Effect of antiviral antibody on maintenance of long-term rubella virus persistent infection in Vero cells. J Virol 1990;64:5183-5187.
2. Achievements in public health: elimination of rubella and congenital rubella syndrome-US, 1969-2004. Ann Pharmacother 2005;39:1151-1152.
3. Adamo P, Asis L, Silveyra P, et al. Rubella virus does not induce apoptosis in primary human embryo fibroblast cultures: a possible way of viral persistence in congenital infection. Viral Immunol 2004;17:87-100.
4. Anderson RM, May RM. Immunisation and herd immunity. Lancet 1990;335:641-645.
5. Atreya CD, Kulkarni S, Mohan KV. Rubella virus P90 associates with the cytokinesis regulatory protein Citron-K kinase and the viral infection and constitutive expression of P90 protein both induce cell cycle arrest following S phase in cell culture. Arch Virol 2004;149:779-789.
6. Auewarakul P. Composition bias and genome polarity of RNA viruses. Virus Res 2005;109:33-37.
7. Banatvala JE, Brown DW. Rubella. Lancet 2004;363:1127-1137.
8. Bardeletti G, Gautheron DC. Phospholipid and cholesterol composition of rubella virus and its host cell BHK 21 grown in suspension cultures. Arch Virol 1976;52:19-27.
9. Bardeletti G, Kessler N, Aymard-Henry M. Morphology, biochemical analysis and neuraminidase activity of rubella virus. Arch Virol 1975;49:175-186.
10. Bardeletti G, Tektoff J, Gautheron D. Rubella virus maturation and production in two host cell systems. Intervirology 1979;11:97-103.
11. Baron MD, Ebel T, Suomalainen M. Intracellular transport of rubella virus structural proteins expressed from cloned cDNA. J Gen Virol 1992;73:1073-1086.
12. Baron MD, Forsell K. Oligomerization of the structural proteins of rubella virus. Virology 1991;185:811-819.
13. Bart SW, Stetler HC, Preblud SR, et al. Fetal risk associated with rubella vaccine: an update. Rev Infect Dis 1985;7(Suppl 1):S95-S102.
14. Basrur S, Stewart A. Information for health care professionals: rubella outbreak in southern Ontario. In O. M. o. Health (ed.), vol. 2. 2005.
15. Beatch MD, Everitt JC, Law LJ, et al. Interactions between rubella virus capsid and host protein p32 are important for virus replication. J Virol 2005;79:10807-10820.
16. Beatch MD, Hobman TC. Rubella virus capsid associates with host cell protein p32 and localizes to mitochondria. J Virol 2000;74:5569-5576.
17. Bechar M, Davidovich S, Goldhammer G, et al. Neurological complications following rubella infection. J Neurol 1982;226:283-287.
18. Berger BE, Omer SB. Could the United States experience rubella outbreaks as a result of vaccine refusal and disease importation? Hum Vaccin 2010;6:1016-1020.
19. Best J, Banatvala J. Rubella. In: Zuckerman A, Banatvala J, Pattison J, et al., eds. Principles and Practice of Clinical Virology. New York: John Wiley & Sons; 2004:428-457.
20. Best JM. Rubella vaccines: past, present and future. Epidemiol Infect 1991;107:17-30.
21. Best JM, Banatvala JE, Bowen JM. New Japanese rubella vaccine: comparative trials. Br Med J 1974;3:221-224.
22. Best JM, Thomson A, Nores JR, et al. Rubella virus strains show no major antigenic differences. Intervirology 1993;34:164-168.
23. Bodansky HJ, Dean BM, Grant PJ, et al. Does exposure to rubella virus generate endocrine autoimmunity? Diabet Med 1990;7:611-614.
24. Bosma TJ, Corbett KM, O'Shea S, et al. PCR for detection of rubella virus RNA in clinical samples. J Clin Microbiol 1995;33:1075-1079.
25. Bottiger B, Jensen IP. Maturation of rubella IgG avidity over time after acute rubella infection. Clin Diagn Virol 1997;8:105-111.
26. Buimovici-Klein E, Cooper LZ. Cell-mediated immune response in rubella infections. Rev Infect Dis 1985;7(Suppl 1):S123-S128.
27. Buynak EB, Hilleman MR, Weibel RE, et al. Live attenuated rubella virus vaccines prepared in duck embryo cell culture. I. Development and clinical testing. JAMA 1968;204:195-200.
28. Centers for Disease Control and Prevention (CDC). Elimination of rubella and congenital rubella syndrome-United States, 1969-2004. Morb Mortal Wkly Rep 2005;54:279-282.
29. Centers for Disease Control and Prevention (CDC). Progress toward control of rubella and prevention of congenital rubella syndrome - worldwide, 2009. Morb Mortal Wkly Rep 2010;59:1307-1310.
30. Centers for Disease Control and Prevention (CDC). Progress toward elimination of measles and prevention of congenital rubella infection-European region, 1990-2004. Morb Mortal Wkly Rep 2005;54:175-178.
31. Centers for Disease Control and Prevention (CDC). Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. Morb Mortal Wkly Rep 2001;50:1117.
32. Centers for Disease Control and Prevention (CDC). Revised ACIP recommendations for avoiding pregnancy after receiving a rubella-containing vaccine. JAMA 2002;287:311-312.
33. Centers for Disease Control and Prevention (CDC). Rubella and congenital rubella-United States, 1984-1986. Morb Mortal Wkly Rep 1987;36:664-666, 671-675.
34. Chantler JK, Davies MA. The effect of antibody on rubella virus infection in human lymphoid cells. J Gen Virol 1987;68(Pt 5):1277-1288.
35. Chantler JK, Ford DK, Tingle AJ. Persistent rubella infection and rubella-associated arthritis. Lancet 1982;1:1323-1325.
36. Chantler JK, Lund KD, Miki NP, et al. Characterization of rubella virus strain differences associated with attenuation. Intervirology 1993;36:225-236.
37. Chantler JK, Tingle AJ. Isolation of rubella virus from human lymphocytes after acute natural infection. J Infect Dis 1982;145:673-677.
38. Chantler JK, Tingle AJ. Replication and expression of rubella virus in human lymphocyte populations. J Gen Virol 1980;50:317-328.
39. Chantler JK, Tingle AJ, Petty RE. Persistent rubella virus infection associated with chronic arthritis in children. N Engl J Med 1985;313:1117-1123.
40. Chaye H, Ou D, Chong P, et al. Human T- and B-cell epitopes of E1 glycoprotein of rubella virus. J Clin Immunol 1993;13:93-100.
41. Chaye HH, Mauracher CA, Tingle AJ, et al. Cellular and humoral immune responses to rubella virus structural proteins E1, E2, and C. J Clin Microbiol 1992;30:2323-2329.
42. Chen JP, Strauss JH, Strauss EG, et al. Characterization of the rubella virus nonstructural protease domain and its cleavage site. J Virol 1996;70:4707-4713.
43. Chen MH, Frey TK. Mutagenic analysis of the 3' cis-acting elements of the rubella virus genome. J Virol 1999;73:3386-3403.
44. Chen MH, Frolov I, Icenogle J, et al. Analysis of the 3' cis-acting elements of rubella virus by using replicons expressing a puromycin resistance gene. J Virol 2004;78:2553-2561.
45. Chen MH, Icenogle JP. Rubella virus capsid protein modulates viral genome replication and virus infectivity. J Virol 2004;78:4314-4322.
46. Clarke DM, Loo TW, Hui I, et al. Nucleotide sequence and in vitro expression of rubella virus 24S subgenomic messenger RNA encoding the structural proteins E1, E2 and C. Nucleic Acids Res 1987;15:3041-3057.
47. Clarke DM, Loo TW, McDonald H, et al. Expression of rubella virus cDNA coding for the structural proteins. Gene 1988;65:23-30.
48. Clarke WL, Shaver KA, Bright GM, et al. Autoimmunity in congenital rubella syndrome. J Pediatr 1984;104:370-373.
49. Claus C, Chey S, Heinrich S, et al. Involvement of p32 and microtubules in alteration of mitochondrial functions by rubella virus. J Virol 2011;85:3881-3892.
50. Cong H, Jiang Y, Tien P. Identification of the myelin oligodendrocyte glycoprotein as a cellular receptor for rubella virus. J Virol 2011;85:11038-11047.
51. Connolly JH, Hutchinson WM, Allen IV, et al. Carotid artery thrombosis, encephalitis, myelitis and optic neuritis associated with rubella virus infections. Brain 1975;98:583-594.
52. Cooper LZ. The history and medical consequences of rubella. Rev Infect Dis 1985;7(Suppl 1):S2-S10.
53. Cooper LZ, Ziring PR, Ockerse AB, et al. Rubella. Clinical manifestations and management. Am J Dis Child 1969;118:18-29.
54. Cordoba P, Lanoel A, Grutadauria S, et al. Evaluation of antibodies against a rubella virus neutralizing domain for determination of immune status. Clin Diagn Lab Immunol 2000;7:964-966.
55. Coyle PK, Wolinsky JS. Characterization of immune complexes in progressive rubella panencephalitis. Ann Neurol 1981;9:557-562.
56. Cradock-Watson JE, Miller E, Ridehalgh MK, et al. Detection of rubella virus in fetal and placental tissues and in the throats of neonates after serologically confirmed rubella in pregnancy. Prenat Diagn 1989;9:91-96.
57. Cui T, Porter AG. Localization of binding site for encephalomyocarditis virus RNA polymerase in the 3'-noncoding region of the viral RNA. Nucleic Acids Res 1995;23:377-382.
58. Cutts FT, Robertson SE, Diaz-Ortega JL, et al. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 1: Burden of disease from CRS. Bull World Health Organ 1997;75:55-68.
59. de Mazancourt A, Waxham MN, Nicolas JC, et al. Antibody response to the rubella virus structural proteins in infants with the congenital rubella syndrome. J Med Virol 1986;19:111-122.
60. Dominguez G, Wang CY, Frey TK. Sequence of the genome RNA of rubella virus: evidence for genetic rearrangement during togavirus evolution. Virology 1990;177:225-238.
61. Duncan R, Muller J, Lee N, et al. Rubella virus-induced apoptosis varies among cell lines and is modulated by Bcl-XL and caspase inhibitors. Virology 1999;255:117-128.
62. Dwyer DE, Robertson PW, Field PR. Broadsheet: clinical and laboratory features of rubella. Pathology 2001;33:322-328.
63. Enders G, Nickerl-Pacher U, Miller E, et al. Outcome of confirmed periconceptional maternal rubella. Lancet 1988;1:1445-1447.
64. Fontana J, Lopez-Iglesias C, Tzeng WP, et al. Three-dimensional structure of Rubella virus factories. Virology 2010;405:579-591.
65. Forbes JA. Rubella: historical aspects. Am J Dis Child 1969;118:5-11.
66. Ford D, Tingle A, Chantler J. Rubella arthritis. In: Espinoza L, Goldberg G, Arnett F, et al., eds. Infections in the Rheumatic Diseases. New York: Grune and Stratton; 1988:103-106.
67. Fraser JR, Cunningham AL, Hayes K, et al. Rubella arthritis in adults. Isolation of virus, cytology and other aspects of the synovial reaction. Clin Exp Rheumatol 1983;1:287-293.
68. Frey TK. Molecular biology of rubella virus. Adv Virus Res 1994;44:69-160.
69. Frey TK, Abernathy ES, Bosma TJ, et al. Molecular analysis of rubella virus epidemiology across three continents, North America, Europe, and Asia, 1961-1997. J Infect Dis 1998;178:642-650.
70. Frey TK, Hemphill ML. Generation of defective-interfering particles by Rubella virus in vero cells. Virology 1988;164:22-29.
71. Froshauer S, Kartenbeck J, Helenius A. Alphavirus RNA replicase is located on the cytoplasmic surface of endosomes and lysosomes. J Cell Biol 1988;107:2075-2086.
72. Gale EA. Congenital rubella: citation virus or viral cause of type 1 diabetes? Diabetologia 2008;51:1559-1566.
73. Garbutt M, Chan H, Hobman TC. Secretion of rubella virions and virus-like particles in cultured epithelial cells. Virology 1999;261:340-346.
74. Garbutt M, Law LM, Chan H, et al. Role of rubella virus glycoprotein domains in assembly of virus-like particles. J Virol 1999;73:3524-3533.
75. Garcia AG, Marques RL, Lobato YY, et al. Placental pathology in congenital rubella. Placenta 1985;6:281-295.
76. Geier DA, Geier MR. Rubella vaccine and arthritic adverse reactions: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database from 1991 through 1998. Clin Exp Rheumatol 2001;19:724-726.
77. Ginsberg-Fellner F, Witt ME, Fedun B, et al. Diabetes mellitus and autoimmunity in patients with the congenital rubella syndrome. Rev Infect Dis 1985;7(Suppl 1):S170-S176.
78. Givens KT, Lee DA, Jones T, et al. Congenital rubella syndrome: ophthalmic manifestations and associated systemic disorders. Br J Ophthalmol 1993;77:358-363.
79. Gomwalk NE, Ahmad AA. Prevalence of rubella antibodies on the African continent. Rev Infect Dis 1989;11:116-121.
80. Gorbalenya AE, Koonin EV, Lai MM. Putative papain-related thiol proteases of positive-strand RNA viruses. Identification of rubi- and aphthovirus proteases and delineation of a novel conserved domain associated with proteases of rubi-, alpha- and coronaviruses. FEBS Lett 1991;288:201-205.
81. Gould JJ, Butler M. Differentiation of rubella virus strains by neutralization kinetics. J Gen Virol 1980;49:423-426.
82. Grangeot-Keros L, Pustowoit B, Hobman T. Evaluation of Cobas Core Rubella IgG EIA recomb, a new enzyme immunoassay based on recombinant rubella-like particles. J Clin Microbiol 1995;33:2392-2394.
83. Gregg NM. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust 1941:35-46.
84. Gros C, Linder M, Wengler G, et al. Analyses of disulfides present in the rubella virus E1 glycoprotein. Virology 1997;230:179-186.
85. Gros C, Wengler G. Identification of an RNA-stimulated NTPase in the predicted helicase sequence of the Rubella virus nonstructural polyprotein. Virology 1996;217:367-372.
86. Hahn YS, Grakoui A, Rice CM, et al. Mapping of RNA- temperature-sensitive mutants of Sindbis virus: Complementation group F mutants have lesions in nsP4. J Virol 1989;63:1194-1202.
87. Hemphill ML, Forng RY, Abernathy ES, et al. Time course of virus-specific macromolecular synthesis during rubella virus infection in Vero cells. Virology 1988;162:65-75.
88. Hethcote HW. Measles and rubella in the United States. Am J Epidemiol 1983;117:2-13.
89. Hinman AR, Irons B, Lewis M, et al. Economic analyses of rubella and rubella vaccines: a global review. Bull World Health Organ 2002;80:264-270.
90. Hobman TC. Targeting of viral glycoproteins to the Golgi complex. Trends Microbiol 1993;1:124-130.
91. Hobman TC, Gillam S. In vitro and in vivo expression of rubella virus glycoprotein E2: the signal peptide is contained in the C-terminal region of capsid protein. Virology 1989;173:241-250.
92. Hobman TC, Lemon HF, Jewell K. Characterization of an endoplasmic reticulum retention signal in the rubella virus E1 glycoprotein. J Virol 1997;71:7670-7680.
93. Hobman TC, Lundstrom ML, Gillam S. Processing and intracellular transport of rubella virus structural proteins in COS cells. Virology 1990;178:122-133.
94. Hobman TC, Lundstrom ML, Mauracher CA, et al. Assembly of rubella virus structural proteins into virus-like particles in transfected cells. Virology 1994;202:574-585.
95. Hobman TC, Qiu ZY, Chaye H, et al. Analysis of rubella virus E1 glycosylation mutants expressed in COS cells. Virology 1991;181:768-772.
96. Hobman TC, Shukin R, Gillam S. Translocation of rubella virus glycoprotein E1 into the endoplasmic reticulum. J Virol 1988;62:4259-4264.
97. Hobman TC, Woodward L, Farquhar MG. Targeting of a heterodimeric membrane protein complex to the Golgi: rubella virus E2 glycoprotein contains a transmembrane Golgi retention signal. Mol Biol Cell 1995;6:7-20.
98. Hobman TC, Woodward L, Farquhar MG. The rubella virus E1 glycoprotein is arrested in a novel post-ER, pre-Golgi compartment. J Cell Biol 1992;118:795-811.
99. Hobman TC, Woodward L, Farquhar MG. The rubella virus E2 and E1 spike glycoproteins are targeted to the Golgi complex. J Cell Biol 1993;121:269-281.
100. Hofmann J, Pletz MW, Liebert UG. Rubella virus-induced cytopathic effect in vitro is caused by apoptosis. J Gen Virol 1999;80(Pt 7):1657-1664.
101. Horstmann DM. Discussion paper: the use of primates in experimental viral infections-rubella and the rubella syndrome. Ann N Y Acad Sci 1969;162:594-597.
102. Horstmann DM. The rubella story, 1881-1985. S Afr Med J 1986;Suppl:60-63.
103. Horstmann DM, Schluederberg A, Emmons JE, et al. Persistence of vaccine-induced immune responses to rubella: comparison with natural infection. Rev Infect Dis 1985;7(Suppl 1):S80-S85.
104. Horzinek M. Non-Arthropod-Born Togaviruses. London: Academic Press; 1981.
105. Ho-Terry L, Londesborough P, Cohen A. Analysis of rubella virus complement-fixing antigens by polyacrylamide gel electrophoresis. Arch Virol 1986;87:219-228.
106. Hukic M, Hubschen JM, Seremet M, et al. An outbreak of rubella in the Federation of Bosnia and Herzegovina between December 2009 and May 2010 indicates failure to vaccinate during wartime (1992-1995). Epidemiol Infect 2011:1-7.
107. Ilkow CS, Goping IS, Hobman TC. The Rubella virus capsid is an anti-apoptotic protein that attenuates the pore-forming ability of Bax. PLoS Pathog 2011;7:e1001291.
108. Ilkow CS, Mancinelli V, Beatch MD, et al. Rubella virus capsid protein interacts with poly(A)-binding protein and inhibits translation. J Virol 2008;82:4284-4294.
109. Ilkow CS, Weckbecker D, Cho WJ, et al. The rubella virus capsid protein inhibits mitochondrial import. J Virol 2010;84:119-130.
110. Johnstone P, Whitby JE, Bosma T, et al. Sequence variation in 5' termini of rubella virus genomes: changes affecting structure of the 5' proximal stem-loop. Arch Virol 1996;141:2471-2477.
111. Kamer G, Argos P. Primary structural comparison of RNA-dependent polymerases from plant, animal and bacterial viruses. Nucleic Acids Res 1984;12:7269-7282.
112. Karounos DG, Wolinsky JS, Thomas JW. Monoclonal antibody to rubella virus capsid protein recognizes a beta-cell antigen. J Immunol 1993;150:3080-3085.
113. Katow S. Rubella virus genome diagnosis during pregnancy and mechanism of congenital rubella. Intervirology 1998;41:163-169.
114. Katow S, Sugiura A. Low pH-induced conformational change of rubella virus envelope proteins. J Gen Virol 1988;69:2797-2807.
115. Kelton JG, Smith JW, Santos AV, et al. Platelet IgG Fc receptor. Am J Hematol 1987;25:299-310.
116. Kouri G, Aguilera A, Rodriguez P, et al. A study of microfoci and inclusion bodies produced by rubella virus in the RK-13 cell line. J Gen Virol 1974;22:73-80.
117. Kresky B, Nauheim JS. Rubella retinitis. Am J Dis Child 1967;113:305-310.
118. Kujala P, Ahola T, Ehsani N, et al. Intracellular distribution of rubella virus nonstructural protein P150. J Virol 1999;73:7805-7811.
119. Law LJ, Ilkow CS, Tzeng WP, et al. Analyses of phosphorylation events in the rubella virus capsid protein: role in early replication events. J Virol 2006;80:6917-6925.
120. Law LM, Duncan R, Esmaili A, et al. Rubella virus E2 signal peptide is required for perinuclear localization of capsid protein and virus assembly. J Virol 2001;75:1978-1983.
121. Law LM, Everitt JC, Beatch MD, et al. Phosphorylation of rubella virus capsid regulates its RNA binding activity and virus replication. J Virol 2003;77:1764-1771.
122. Lee JY, Bowden DS. Rubella virus replication and links to teratogenicity. Clin Microbiol Rev 2000;13:571-587.
123. Lee JY, Bowden DS, Marshall JA. Membrane junctions associated with rubella virus infected cells. J Submicrosc Cytol Pathol 1996;28:101-108.
124. Lee JY, Hwang D, Gillam S. Dimerization of rubella capsid protein is not required for virus particle formation. Virology 1996;216:223-227.
125. Lee JY, Marshall JA, Bowden DS. Characterization of rubella virus replication complexes using antibodies to double-stranded RNA. Virology 1994;200:307-312.
126. Lee JY, Marshall JA, Bowden DS. Localization of rubella virus core particles in vero cells. Virology 1999;265:110-119.
127. Lee JY, Marshall JA, Bowden DS. Replication complexes associated with the morphogenesis of rubella virus. Arch Virol 1992;122:95-106.
128. Liang Y, Gillam S. Mutational analysis of the rubella virus nonstructural polyprotein and its cleavage products in virus replication and RNA synthesis. J Virol 2000;74:5133-5141.
129. Liang Y, Yao J, Gillam S. Rubella virus nonstructural protein protease domains involved in trans- and cis-cleavage activities. J Virol 2000;74:5412-5423.
130. Liu X, Ropp SL, Jackson RJ, et al. The rubella virus nonstructural protease requires divalent cations for activity and functions in trans. J Virol 1998;72:4463-4466.
131. Liu X, Yang J, Ghazi AM, et al. Characterization of the zinc binding activity of the rubella virus nonstructural protease. J Virol 2000;74:5949-5956.
132. Liu Z, Yang D, Qiu Z, et al. Identification of domains in rubella virus genomic RNA and capsid protein necessary for specific interaction. J Virol 1996;70:2184-2190.
133. Londesborough P, Ho-Terry L, Terry G. Sequence variation and biological activity of rubella virus isolates. Arch Virol 1995;140:563-570.
134. Lovett AE, McCarthy M, Wolinsky JS. Mapping cell-mediated immunodominant domains of the rubella virus structural proteins using recombinant proteins and synthetic peptides. J Gen Virol 1993;74:445-452.
135. Lund KD, Chantler JK. Mapping of genetic determinants of rubella virus associated with growth in joint tissue. J Virol 2000;74:796-804.
136. Lundstrom ML, Mauracher CA, Tingle AJ. Characterization of carbohydrates linked to rubella virus glycoprotein E2. J Gen Virol 1991;72:843-850.
137. Mace M, Cointe D, Six C, et al. Diagnostic value of reverse transcription-PCR of amniotic fluid for prenatal diagnosis of congenital rubella infection in pregnant women with confirmed primary rubella infection. J Clin Microbiol 2004;42:4818-4820.
138. Magliano D, Marshall JA, Bowden DS, et al. Rubella virus replication complexes are virus-modified lysosomes. Virology 1998;240:57-63.
139. Marr LD, Sanchez A, Frey TK. Efficient in vitro translation and processing of the rubella virus structural proteins in the presence of microsomes. Virology 1991;180:400-405.
140. Marr LD, Wang CY, Frey TK. Expression of the rubella virus nonstructural protein ORF and demonstration of proteolytic processing. Virology 1994;198:586-592.
141. Marttila J, Ilonen J, Lehtinen M, et al. Definition of three minimal T helper cell epitopes of rubella virus E1 glycoprotein. Clin Exp Immunol 1996;104:394-397.
142. Mastromarino P, Cioe L, Rieti S, et al. Role of membrane phospholipids and glycolipids in the Vero cell surface receptor for rubella virus. Med Microbiol Immunol (Berl) 1990;179:105-114.
143. Maton W. Some account of a rash liable to be mistaken for scarlatina. Med Trans Coll Physicians (London) 1815;5:149-165.
144. Matsumoto A, Higashi M. Electron microscopic studies on the morphology and morphogenesis of togaviruses. Ann Rep Inst Virus Res Kyoto Univ 1974;17:11-12.
145. Mauracher CA, Gillam S, Shukin R, et al. pH-dependent solubility shift of rubella virus capsid protein. Virology 1991;181:773-777.
146. Mauracher CA, Mitchell LA, Tingle AJ. Differential IgG avidity to rubella virus structural proteins. J Med Virol 1992;36:202-208.
147. McCarthy M, Lovett A, Kerman RH, et al. Immunodominant T-cell epitopes of rubella virus structural proteins defined by synthetic peptides. J Virol 1993;67:673-681.
148. McIntosh ED, Menser MA. A fifty-year follow-up of congenital rubella. Lancet 1992;340:414-415.
149. Megyeri K, Berencsi K, Halazonetis TD, et al. Involvement of a p53-dependent pathway in rubella virus-induced apoptosis. Virology 1999;259:74-84.
150. Melancon P, Garoff H. Processing of the Semliki Forest virus structural polyprotein: role of the capsid protease. J Virol 1987;61:1301-1309.
151. Menser MA, Dods L, Harley JD. A twenty-five-year follow-up of congenital rubella. Lancet 1967;2:1347-1350.
152. Miki NP, Chantler JK. Differential ability of wild-type and vaccine strains of rubella virus to replicate and persist in human joint tissue. Clin Exp Rheumatol 1992;10:3-12.
153. Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982;2:781-784.
154. Mitchell LA, Decarie D, Tingle AJ, et al. Identification of immunoreactive regions of rubella virus E1 and E2 envelope proteins by using synthetic peptides. Virus Res 1993;29:33-57.
155. Mitchell LA, Tingle AJ, MacWilliam L, et al. HLA-DR class II associations with rubella vaccine-induced joint manifestations. J Infect Dis 1998;177:5-12.
156. Mitchell LA, Tingle AJ, Shukin R, et al. Chronic rubella vaccine-associated arthropathy. Arch Intern Med 1993;153:2268-2274.
157. Mitchell LA, Zhang T, Ho M, et al. Characterization of rubella virus-specific antibody responses by using a new synthetic peptide-based enzyme-linked immunosorbent assay. J Clin Microbiol 1992;30:1841-1847.
158. Mitchell LA, Zhang T, Tingle AJ. Differential antibody responses to rubella virus infection in males and females. J Infect Dis 1992;166:1258-1265.
159. Murphy F. Togavirus morphology and morphogenesis. In: S. RW, ed. The Togaviruses. New York: Academic Press; 1980:241-316.
160. Murphy FA, Halonen PE, Harrison AK. Electron microscopy of the development of rubella virus in BHK-21 cells. J Virol 1968;2:1223-1227.
161. Naeye RL, Blanc W. Pathogenesis of congenital rubella. JAMA 1965;194:1277-1283.
162. Ogra PL, Herd JK. Arthritis associated with induced rubella infection. J Immunol 1971;107:810-813.
163. Oka JA, Weigel PH. Microtubule-depolymerizing agents inhibit asialo-orosomucoid delivery to lysosomes but not its endocytosis or degradation in isolated rat hepatocytes. Biochim Biophys Acta 1983;763:368-376.
164. Okamoto K, Fujii K, Komase K. Development of a novel TaqMan real-time PCR assay for detecting rubella virus RNA. J Virol Methods 2010;168:267-271.
165. Oker-Blom C. The gene order for Rubella virus structural proteins is NH2-C-E2-E1-COOH. J Virol 1984;51:354-358.
166. Oker-Blom C, Ulmanen I, Kaariainen L, et al. Rubella virus 40S genome RNA specifies a 24S subgenomic mRNA that codes for a precursor to structural proteins. J Virol 1984;49:403-408.
167. O'Shea S, Best JM, Banatvala JE. Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J Infect Dis 1983;148:639-647.
168. O'Shea S, Woodward S, Best JM, et al. Rubella vaccination: persistence of antibodies for 10-21 years. Lancet 1988;2:909.
169. Otsuki N, Abo H, Kubota T, et al. Elucidation of the full genetic information of Japanese rubella vaccines and the genetic changes associated with in vitro and in vivo vaccine virus phenotypes. Vaccine 2011;29:1863-1873.
170. Ou D, Chong P, Choi Y, et al. Identification of T-cell epitopes on E2 protein of rubella virus, as recognized by human T-cell lines and clones. J Virol 1992;66:6788-6793.
171. Ou D, Chong P, McVeish P, et al. Characterization of the specificity and genetic restriction of human CD4+ cytotoxic T cell clones reactive to capsid antigen of rubella virus. Virology 1992;191:680-686.
172. Ou D, Chong P, Tingle AJ, et al. Mapping T-cell epitopes of rubella virus structural proteins E1, E2, and C recognized by T-cell lines and clones derived from infected and immunized populations. J Med Virol 1993;40:175-183.
173. Ou D, Chong P, Tripet B, et al. Analysis of T- and B-cell epitopes of capsid protein of rubella virus by using synthetic peptides. J Virol 1992;66:1674-1681.
174. Ou D, Jonsen LA, Metzger DL, et al. CD4+ and CD8+ T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes. Implications for HLA class I and II allelic linkage to disease susceptibility. Hum Immunol 1999;60:652-664.
175. Ou D, Mitchell LA, Decarie D, et al. Characterization of an overlapping CD8+ and CD4+ T-cell epitope on rubella capsid protein. Virology 1997;235:286-292.
176. Ou D, Mitchell LA, Decarie D, et al. Promiscuous T-cell recognition of a rubella capsid protein epitope restricted by DRB1*0403 and DRB1*0901 molecules sharing an HLA DR supertype. Hum Immunol 1998;59:149-157.
177. Ou D, Mitchell LA, Domeier ME, et al. Characterization of the HLA-restrictive elements of a rubella virus-specific cytotoxic T cell clone: influence of HLA-DR4 beta chain residue 74 polymorphism on antigenic peptide-T cell interaction. Int Immunol 1996;8:1577-1586.
178. Ou D, Mitchell LA, Ho M, et al. Analysis of overlapping T- and B-cell antigenic sites on rubella virus E1 envelope protein. Influence of HLA-DR4 polymorphism on T-cell clonal recognition. Hum Immunol 1994;39:177-187.
179. Ou D, Mitchell LA, Metzger DL, et al. Cross-reactive rubella virus and glutamic acid decarboxylase (65 and 67) protein determinants recognised by T cells of patients with type I diabetes mellitus. Diabetologia 2000;43:750-762.
180. Pappas CL, Tzeng WP, Frey TK. Evaluation of cis-acting elements in the rubella virus subgenomic RNA that play a role in its translation. Arch Virol 2006;151:327-346.
181. Parkman PD. Biological Characteristics of Rubella Virus. Arch Gesamte Virusforsch 1965;16:401-411.
182. Parkman PD, Buescher EL, Artenstein MS. Recovery of rubella virus from army recruits. Proc Soc Exp Biol Med 1962;111:225-230.
183. Paschen SA, Weber A, Hacker G. Mitochondrial protein import: a matter of death? Cell Cycle 2007;6:2434-2439.
184. Peetermans J. Factors affecting the stability of viral vaccines. Dev Biol Stand 1996;87:97-101.
185. Peetermans J, Huygelen C. Attenuation ob rubella virus by serial passage in primary rabbit kidney cell cultures. I. Growth characteristics in vitro and production of experimental vaccines at different passage levels. Arch Gesamte Virusforsch 1967;21:133-143.
186. Petruzziello R, Orsi N, Macchia S, et al. Pathway of rubella virus infectious entry into Vero cells. J Gen Virol 1996;77:303-308.
187. Plotkin SA. Routes of fetal infection and mechanisms of fetal damage. Am J Dis Child 1975;129:444-449.
188. Plotkin SA, Farquhar J, Katz M, et al. A new attenuated rubella virus grown in human fibroblasts: evidence for reduced nasopharyngeal excretion. Am J Epidemiol 1967;86:468-477.
189. Polk BF, Modlin JF, White JA, et al. A controlled comparison of joint reactions among women receiving one of two rubella vaccines. Am J Epidemiol 1982;115:19-25.
190. Pougatcheva SO, Abernathy ES, Vzorov AN, et al. Development of a rubella virus DNA vaccine. Vaccine 1999;17:2104-2112.
191. Preblud SR, Williams NM. Fetal risk associated with rubella vaccine: implications for vaccination of susceptible women. Obstet Gynecol 1985;66:121-123.
192. Pugachev KV, Abernathy ES, Frey TK. Genomic sequence of the RA27/3 vaccine strain of rubella virus. Arch Virol 1997;142:1165-1180.
193. Pugachev KV, Abernathy ES, Frey TK. Improvement of the specific infectivity of the rubella virus (RUB) infectious clone: determinants of cytopathogenicity induced by RUB map to the nonstructural proteins. J Virol 1997;71:562-568.
194. Pugachev KV, Frey TK. Effects of defined mutations in the 5' nontranslated region of rubella virus genomic RNA on virus viability and macromolecule synthesis. J Virol 1998;72:641-650.
195. Pugachev KV, Frey TK. Rubella virus induces apoptosis in culture cells. Virology 1998;250:359-370.
196. Pugachev KV, Galinski MS, Frey TK. Infectious cDNA clone of the RA27/3 vaccine strain of Rubella virus. Virology 2000;273:189-197.
197. Pustowoit B, Liebert UG. Predictive value of serological tests in rubella virus infection during pregnancy. Intervirology 1998;41:170-177.
198. Qiu Z, Hobman TC, McDonald HL, et al. Role of N-linked oligosaccharides in processing and intracellular transport of E2 glycoprotein of rubella virus. J Virol 1992;66:3514-3521.
199. Qiu Z, Ou D, Hobman TC, et al. Expression and characterization of virus-like particles containing rubella virus structural proteins. J Virol 1994;68:4086-4091.
200. Qiu Z, Yao J, Cao H, et al. Mutations in the E1 hydrophobic domain of rubella virus impair virus infectivity but not virus assembly. J Virol 2000;74:6637-6642.
201. Rabinowe SL, George KL, Loughlin R, et al. Congenital rubella. Monoclonal antibody-defined T cell abnormalities in young adults. Am J Med 1986;81:779-782.
202. Rand ML, Wright JF. Virus-associated idiopathic thrombocytopenic purpura. Transfus Sci 1998;19:253-259.
203. Rawls WE. Congenital rubella: the significance of virus persistence. Prog Med Virol 1968;10:238-285.
204. Rayfield EJ, Kelly KJ, Yoon JW. Rubella virus-induced diabetes in the hamster. Diabetes 1986;35:1278-1281.
205. Revello MG, Baldanti F, Sarasini A, et al. Prenatal diagnosis of rubella virus infection by direct detection and semiquantitation of viral RNA in clinical samples by reverse transcription-PCR. J Clin Microbiol 1997;35:708-713.
206. Risco C, Carrascosa JL, Frey TK. Structural maturation of rubella virus in the Golgi complex. Virology 2003;312:261-269.
207. Rittler M, Lopez-Camelo J, Castilla EE. Monitoring congenital rubella embryopathy. Birth Defects Res A Clin Mol Teratol 2004;70:939-943.
208. Robertson SE, Cutts FT, Samuel R, et al. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: Vaccination against rubella. Bull World Health Organ 1997;75:69-80.
209. Robertson SE, Featherstone DA, Gacic-Dobo M, et al. Rubella and congenital rubella syndrome: global update. Rev Panam Salud Publica 2003;14:306-315.
210. Rorke LB. Nervous system lesions in the congenital rubella syndrome. Arch Otolaryngol 1973;98:249-251.
211. Rozanov MN, Koonin EV, Gorbalenya AE. Conservation of the putative methyltransferase domain: a hallmark of the 'Sindbis-like' supergroup of positive-strand RNA viruses. J Gen Virol 1992;73:2129-2134.
212. Sarnesto A, Ranta S, Vaananen P, et al. Proportions of Ig classes and subclasses in rubella antibodies. Scand J Immunol 1985;21:275-282.
213. Schluter WW, Reef SE, Redd SC, et al. Changing epidemiology of congenital rubella syndrome in the United States. J Infect Dis 1998;178:636-641.
214. Sedwick WD, Sokol F. Nucleic acid of rubella virus and its replication in hamster kidney cells. J Virol 1970;5:478-489.
215. Sever JL, South MA, Shaver KA. Delayed manifestations of congenital rubella. Rev Infect Dis 1985;7(Suppl 1):S164-S169.
216. Shaver KA, Boughman JA, Nance WE. Congenital rubella syndrome and diabetes: a review of epidemiologic, genetic, and immunologic factors. Am Ann Deaf 1985;130:526-532.
217. Shirley JA, Revill S, Cohen BJ, et al. Serological study of rubella-like illnesses. J Med Virol 1987;21:369-379.
218. Shishido A, Ohtawara M. Development of attenuated rubella virus vaccines in Japan. Jpn J Med Sci Biol 1976;29:227-253.
219. Smith CA, Petty RE, Tingle AJ. Rubella virus and arthritis. Rheum Dis Clin North Am 1987;13:265-274.
220. Squadrini F, Taparelli F, De Rienzo B, et al. Rubella virus isolation from cerebrospinal fluid in postnatal rubella encephalitis. Br Med J 1977;2:1329-1330.
221. Standardization of the nomenclature for genetic characteristics of wild-type rubella viruses. Wkly Epidemiol Rec 2005;80:126-132.
222. Stanwick TL, Hallum JV. Role of interferon in six cell lines persistently infected with rubella virus. Infect Immun 1974;10:810-815.
223. Strauss JH, Strauss EG, Kuhn RJ. Budding of alphaviruses. Trends Microbiol 1995;3:346-350.
224. Suomalainen M, Garoff H, Baron MD. The E2 signal sequence of rubella virus remains part of the capsid protein and confers membrane association in vitro. J Virol 1990;64:5500-5509.
225. Takkinen K, Vidgren G, Ekstrand J, et al. Nucleotide sequence of the rubella virus capsid protein gene reveals an unusually high G/C content. J Gen Virol 1988;69:603-612.
226. Thomas HI, Barrett E, Hesketh LM, et al. Simultaneous IgM reactivity by EIA against more than one virus in measles, parvovirus B19 and rubella infection. J Clin Virol 1999;14:107-118.
227. Thomas HI, Morgan-Capner P, Cradock-Watson JE, et al. Slow maturation of IgG1 avidity and persistence of specific IgM in congenital rubella: implications for diagnosis and immunopathology. J Med Virol 1993;41:196-200.
228. Thomas HI, Morgan-Capner P, Enders G, et al. Persistence of specific IgM and low avidity specific IgG1 following primary rubella. J Virol Methods 1992;39:149-155.
229. Tingle AJ, Allen M, Petty RE, et al. Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation. Ann Rheum Dis 1986;45:110-114.
230. Tingle AJ, Chantler JK, Kettyls GD, et al. Failed rubella immunization in adults: association with immunologic and virological abnormalities. J Infect Dis 1985;151:330-336.
231. Tingle AJ, Mitchell LA, Grace M, et al. Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women. Lancet 1997;349:1277-1281.
232. Tipples G, Hiebert J. Detection of measles, mumps, and rubella viruses. Methods Mol Biol 2011;665:183-193.
233. Tondury G, Smith DW. Fetal rubella pathology. J Pediatr 1966;68:867-879.
234. Townsend JJ, Baringer JR, Wolinsky JS, et al. Progressive rubella panencephalitis. Late onset after congenital rubella. N Engl J Med 1975;292:990-993.
235. Trudel M, Marchessault F, Payment P. Characterisation of rubella virus hemagglutinin rosettes. J Virol Methods 1981;2:195-201.
236. Trudel M, Ravaoarinoro M, Payment P. Reconstitution of rubella hemagglutinin on liposomes. Can J Microbiol 1980;26:899-904.
237. Tzeng WP, Chen MH, Derdeyn CA, et al. Rubella virus DI RNAs and replicons: requirement for nonstructural proteins acting in cis for amplification by helper virus. Virology 2001;289:63-73.
238. Tzeng WP, Frey TK. Complementation of a deletion in the rubella virus p150 nonstructural protein by the viral capsid protein. J Virol 2003;77:9502-9510.
239. Tzeng WP, Frey TK. Rubella virus capsid protein modulation of viral genomic and subgenomic RNA synthesis. Virology 2005;337:327-334.
240. Ueda K, Shingaki Y, Sato T, et al. Hemolytic anemia following postnatally acquired rubella during the 1975-1977 rubella epidemic in Japan. Clin Pediatr (Phila) 1985;24:155-157.
241. Vaheri A, Sedwick WD, Plotkin SA. Growth of rubella virus in BHK21 cells. II. Enhancing effect of DEAE-dextran, semicarbazide and low doses of metabolic inhibitors. Proc Soc Exp Biol Med 1967;125:1092-1098.
242. Vaheri A, Sedwick WD, Plotkin SA, et al. Cytopathic effect of rubella virus in RHK21 cells and growth to high titers in suspension culture. Virology 1965;27:239-241.
243. Veale H. History of an epidemic of Rõtheln with observations on its pathology. Edinburgh Med J 1866;12:404-414.
244. von Bonsdorff C-H, Vaheri A. Growth of rubella virus in BHK-21 cells: electron microscopy of morphogenesis. J Gen Virol 1969;5:47-51.
245. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-641.
246. Wang C-Y, Dominguez G, Frey TK. Construction of rubella virus genome-length cDNA clones and synthesis of infectious RNA transcripts. J Virol 1994;68:3550-3557.
247. Wang SS, Han YR, Su WN, et al. Studies on the reactogenicity and immunogenicity of the BRD-2 and RA27/3 live attenuated rubella vaccines. Vaccine 1984;2:277-280.
248. Wang Z, Yao P, Song Y, et al. Characteristics and mechanisms of isolated rubella virus, strain JR23: infection of the central nervous system of BALB/c mice. Intervirology 2003;46:79-85.
249. Waxham MN, Wolinsky JS. Detailed immunologic analysis of the structural polypeptides of rubella virus using monoclonal antibodies. Virology 1985;143:153-165.
250. Waxham MN, Wolinsky JS. Rubella virus and its effects on the central nervous system. Neurol Clin 1984;2:367-385.
251. Webster WS. Teratogen update: congenital rubella. Teratology 1998;58:13-23.
252. Weil ML, Itabashi H, Cremer NE, et al. Chronic progressive panencephalitis due to rubella virus simulating subacute sclerosing panencephalitis. N Engl J Med 1975;292:994-998.
253. Weller TH, Neva FA. Propagation in tissue culture of cytopathic agents from patients with rubella-like illness. Proc Soc Exp Biol Med 1962;111:215-225.
254. Wesselhoeft C. Rubella (German measles). N Engl J Med 1947;236:943-950.
255. Williams MP, Brawner TA, Riggs HG Jr, et al. Characteristics of a persistent rubella infection in a human cell line. J Gen Virol 1981;52:321-328.
256. Wolinsky JS, McCarthy M, Allen-Cannady O, et al. Monoclonal antibody-defined epitope map of expressed rubella virus protein domains. J Virol 1991;65:3986-3994.
257. Wolinsky JS, Sukholutsky E, Moore WT, et al. An antibody- and synthetic peptide-defined rubella virus E1 glycoprotein neutralization domain. J Virol 1993;67:961-968.
258. World Health Organization. WHO vaccine-preventable diseases monitoring system, 2009 global summary. Geneva: World Health Organization, 2009.
259. Yao J, Gillam S. Mutational analysis, using a full-length rubella virus cDNA clone, of rubella virus E1 transmembrane and cytoplasmic domains required for virus release. J Virol 1999;73:4622-4630.
260. Yao J, Yang D, Chong P, et al. Proteolytic processing of rubella virus nonstructural proteins. Virology 1998;246:74-82.
261. Yoneda T, Urade M, Sakuda M, et al. Altered growth, differentiation, and responsiveness to epidermal growth factor of human embryonic mesenchymal cells of palate by persistent rubella virus infection. J Clin Invest 1986;77:1613-1621.
262. Yoon JW, Choi DS, Liang HC, et al. Induction of an organ-specific autoimmune disease, lymphocytic hypophysitis, in hamsters by recombinant rubella virus glycoprotein and prevention of disease by neonatal thymectomy. J Virol 1992;66:1210-1214.
263. Zheng DP, Frey TK, Icenogle J, et al. Global distribution of rubella virus genotypes. Emerg Infect Dis 2003;9:1523-1530.
264. Zhou Y, Ushijima H, Frey TK. Genomic analysis of diverse rubella virus genotypes. J Gen Virol 2007;88:932-941.
265. Zimmernman L, Reef S. Rubella. In VPD Surveillance Manual. Atlanta, GA: CDC; 2002:1-12.